Publication | Open Access

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Hematological MalignancyOncologyPacritinib VersusImmunologyClinical TrialsHematologyMyeloid NeoplasiaBaseline CytopeniasPharmacotherapyMedicineAvailable TherapyHealth Sciences